title: [Bacterial prostatitis and prostatic fibrosis: modern view on the treatment and prophylaxis].
abstract: Treatments of chronic bacterial prostatitis (CP) remain difficult problem. Bacterial prostatitis is a disease entity diagnosed clinically and by evidence of inflammation and infection localized to the prostate. Risk factors for UTI in men include urological interventions, such as transrectal prostate biopsy. Ensuing infections after prostate biopsy, such as UTI and bacterial prostatitis, are increasing due to increasing rates of fluoroquinolone resistance. The increasing global antibiotic resistance also significantly affects management of UTI in men, and therefore calls for alternative strategies. Prostatic inflammation has been suggested to contribute to the etiology of lower urinary tract symptoms (LUTS) by inducing fibrosis. Several studies have shown that prostatic fibrosis is strongly associated with impaired urethral function and LUTS severity. Fibrosis resulting from excessive deposition of collagen is traditionally recognized as a progressive irreversible condition and an end stage of inflammatory diseases; however, there is compelling evidence in both animal and human studies to support that the development of fibrosis could potentially be a reversible process. Prostate inflammation may induce fibrotic changes in periurethral prostatic tissues, promote urethral stiffness and LUTS. Patients experiencing CP and prostate-related LUTS could benefit from anti-inflammatory therapies, especially used in combination with the currently prescribed enzyme treatment with Longidase. Treatment results showed that longidase is highly effective in bacterial and abacterial CP. Longidase addition to standard therapeutic methods significantly reduced the disease symptoms and regression of inflammatory-proliferative alterations in the prostate.
authors.affiliation: SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH, Moscow.
authors.forename: A V
authors.initials: AV
authors.lastname: Zaitsev
authors.affiliation: SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH, Moscow.
authors.forename: D Yu
authors.initials: DY
authors.lastname: Pushkar
authors.affiliation: Government of Moscow Department of Health Scientific Research Institute of HealthCare Organization of and Medical Management Moscow Department of HealthCare.
authors.forename: L A
authors.initials: LA
authors.lastname: Khodyreva
authors.affiliation: Government of Moscow Department of Health Scientific Research Institute of HealthCare Organization of and Medical Management Moscow Department of HealthCare.
authors.forename: A A
authors.initials: AA
authors.lastname: Dudareva
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D005355:Fibrosis; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D008297:Male; D011108:Polymers / Q000627:therapeutic use; D011469:Prostatic Diseases / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D011472:Prostatitis / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology
chemical_list: D011108:Polymers; D006821:Hyaluronoglucosaminidase; C000597018:Longidaza
keywords: Longidase; enzyme treatment; prostate; prostatic fibrosis; prostatitis